Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the potential of Kiniksa's KPL-404 and Aclaris's zunsemetinib (ATI-450) for treatment of patients with rheumatoid arthritis

Ticker(s): KNSA, ACRS

Who's the expert?

Institution: Mayo Clinic

Rheumatologists at the Mayo Clinic in Jacksonville Florida with a treatment focus on Vasculitis, Behcets, Rheumatoid Arthritis, and Gout.
Currently manages 40 patients with rheumatoid arthritis and has read through the phase 1 early stage data regarding KPL-404.
Research focuses on Rheumatoid Arthritis, Lupus, and Vasculitis.

Interview Goal

This call will focus on reviewing phase 1 early stage data from the trials regarding the potential of Kiniksa's KPL-404, currently in development for treating patients with rheumatoid arthritis by blocking CD40/CD40L interactions. Also comparing with Aclaris' zunsemetinib (ATI-450), a MK2 inhibitor for treatment of rheumatoid arthritis

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.